N-(1-azabicyclo[2.2.2]octan-3-yl)-1-(difluoromethyl)-6-methoxyindazole-3-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: N-(1-azabicyclo[2.2.2]octan-3-yl)-1-(difluoromethyl)-6-methoxyindazole-3-carboxamide
• 化学式: C₁₇H₂₀F₂N₄O₂
• 分子量: 350.36
• InChiKey: VQDFGMVDXFKJGX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• 5-HT3 RECEPTOR ANTAGONISTS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20160185801A1

  公开（公告）日：2016-06-30

  The present invention provides compounds of the formula: that are 5HT3 receptor antagonists and are therefore useful for the treatment of diseases treatable by inhibition of 5HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

  本发明提供的化合物具有以下公式： 这些化合物是5HT3受体拮抗剂，因此可用于治疗可通过抑制5HT3受体治疗的疾病，例如呕吐、疼痛、药物成瘾、神经退行性和精神障碍以及胃肠道疾病。还提供了包含这些化合物的制药组合物和制备这些化合物的方法。
• 5HT3 RECEPTOR ANTAGONISTS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2875012A1

  公开（公告）日：2015-05-27
• US9303045B2
  申请人：——

  公开号：US9303045B2

  公开（公告）日：2016-04-05
• US9695195B2
  申请人：——

  公开号：US9695195B2

  公开（公告）日：2017-07-04
• [EN] 5HT3 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RÉCEPTEUR 5HT3
  申请人：ENVOY THERAPEUTICS INC

  公开号：WO2014014962A1

  公开（公告）日：2014-01-23

  The present invention provides compounds of the formula: (I) that are 5HT3 receptor antagonists and are therefore useful for the treatment of diseases treatable by inhibition of 5HT3 receptor such as emesis, pain, drug addiction, neurodegenerative and psychiatric disorders, and GI disorders. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.